+134.1%
MRVL vs GSK
+43.9%
+90.2%
-61.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +9.3% | -1.2% | +10.6% | +9.4% |
| 7D | +5.6% | -1.1% | +6.7% | +5.7% |
| 30D | -36.5% | +7.8% | -44.4% | -36.7% |
| 3M | -20.5% | +0.3% | -20.8% | -20.4% |
| 6M | -1.1% | +3.4% | -4.6% | -1.8% |
| YTD | +99.0% | +5.9% | +93.1% | +97.5% |
| 1Y | +89.3% | +8.2% | +81.1% | +87.4% |
| 3Y | +211.6% | +65.3% | +146.4% | +178.3% |
| 5Y | +134.1% | +43.3% | +90.7% | +112.8% |
| All | +134.1% | +43.9% | +90.2% | +112.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling